Sagimet Biosciences Revenue and Competitors

Location

$293.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Sagimet Biosciences's estimated annual revenue is currently $1.5M per year.(i)
  • Sagimet Biosciences's estimated revenue per employee is $100,500
  • Sagimet Biosciences's total funding is $293.7M.

Employee Data

  • Sagimet Biosciences has 15 Employees.(i)
  • Sagimet Biosciences grew their employee count by 15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.4M2-67%N/AN/A
#2
$32M1593%N/AN/A
#3
$35M1213%$62.5MN/A
#4
$30.2M15018%N/AN/A
#5
$135.9M676-1%N/AN/A
#6
$14.9M972%$173MN/A
#7
$110.3M549N/AN/AN/A
#8
$62.7M312-3%N/AN/A
#9
$4.9M4932%N/AN/A
#10
$9.2M46-2%N/AN/A
Add Company

3-V Biosciences was founded by The Column Group (TCG) and Kleiner Perkins Caulfield & Byers (KPCB) in March 2007. In April 2007, the original laboratory was opened in Zürich, Switzerland in close proximity to the company’s founders at the ETH (Swiss Federal Institute of Technology) and the University of Zürich. Host pathway screening began in November 2007 and continues today

keywords:N/A

$293.7M

Total Funding

15

Number of Employees

$1.5M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Sagimet Biosciences News

2022-04-20 - Has the war in Ukraine caused an IPO market slowdown?

... mall unit in Hong Kong; liver disease and cancer biotech firm Sagimet Biosciences; and stroke treatment startup Bioxytran [BIXT].

2022-03-22 - Sagimet Biosciences Withdraws Planned IPO

Clinical-stage biopharmaceutical company Sagimet Biosciences Inc. has dropped plans for an initial public offering. The San Mateo, Calif.,...

2022-03-22 - Going...going...gone. A small biotech throws in its IPO cards ...

If you were looking for another sign of the woeful conditions on Wall Street for biotechs, you can tee up the latest from Sagimet Biosciences. George Kemble.

2021-03-16 - Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH

SAN MATEO, Calif., March 16, 2021 /PRNewswire/ -- Sagimet Biosciences Inc., a clinical-stage biotechnology company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors, announced today that the U.S. Food and Drug Administration (FDA) has g ...

2021-02-12 - Sagimet Biosciences Raises $80M in Crossover Financing

Sagimet Biosciences, a San Mateo, Calif.-based clinical-stage biotechnology company, raised $80m in crossover financing. The round was led by an undisclosed public equity healthcare investment fund with participation from existing investors (including Ascletis, Kleiner Perkins, New Enterprise A ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A15-44%N/A
#2
$0.6M1525%$7.5M
#3
$1.3M15N/AN/A
#4
$0.5M15-37%$74.7M
#5
$1.3M15N/AN/A